These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 39262463)

  • 1. Efficacy and safety of immune checkpoint inhibitors plus platinum-etoposide
    Chen Y; Shang H; Yang Y; Wang Q; Gao X; Huang G
    Transl Cancer Res; 2024 Aug; 13(8):4146-4158. PubMed ID: 39262463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J; Deng Y; Huang B; Chen X
    Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
    Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
    Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
    Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
    Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
    Peng TR; Lin HH; Tsai FP; Wu TW
    Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
    Chen C; Tian P; Zhong J; Fan X
    Front Oncol; 2023; 13():1151769. PubMed ID: 37152041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    He M; Wu B; Liu Q; Fang Z; Liu M; Yi F; Wei Y; Peng J; Zhang W
    Chemotherapy; 2021; 66(4):113-123. PubMed ID: 34515066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.